ReviewNeoplasia (New York, N.Y.)2006
Ubiquitin and ubiquitin-like modifications of the p53 family.
Review in Neoplasia (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 74 citations in OpenAlex.
- DoUBLing up: ubiquitin and ubiquitin-like proteases in genome stability.The Biochemical journal · 2024Review
- Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.MedComm · 2023Review
- SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.Blood advances · 2023Article
- P53 protein and the diseases in central nervous system.Frontiers in genetics · 2022Review
- Identification of proximal SUMO-dependent interactors using SUMO-ID.Nature communications · 2021Article
- Tmub1 Suppresses Hepatocellular Carcinoma by Promoting the Ubiquitination of ΔNp63 Isoforms.Molecular therapy oncolytics · 2020Article
- Post-translational modification of Parkin and its research progress in cancer.Cancer communications (London, England) · 2019Review
- RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Pharmaceutical research · 2017Review
- The molecular determinants for distinguishing between ubiquitin and NEDD8 by USP2.Scientific reports · 2017Article
- Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells.Journal of cellular and molecular medicine · 2014Article
- A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.International journal of nanomedicine · 2014Article
- Lysine-specific modifications of p53: a matter of life and death?Oncotarget · 2013Review
- Regulatory feedback loop between TP73 and TRIM32.Cell death & disease · 2013Article
- Article
- UBE4B: a promising regulatory molecule in neuronal death and survival.International journal of molecular sciences · 2012Review
- Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.FEBS letters · 2012Review
- Covalent NEDD8 conjugation increases RCAN1 protein stability and potentiates its inhibitory action on calcineurin.PloS one · 2012Article
- A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma.Oncotarget · 2011Article
- Alternative allosteric mechanisms can regulate the substrate and E2 in SUMO conjugation.Journal of molecular biology · 2011Article
- A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.The Journal of clinical investigation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulation of p53 by the ubiquitin-proteasomal pathway has been studied considerably. Studies have also demonstrated that the ubiquitin-like proteins SUMO-1 and NEDD8 modify p53. Similarly, p63 and p73 are subject to regulation by ubiquitin and ubiquitin-like modifications, and perturbations of these pathways in the regulation of the p53 family have been implicated in tumorigenesis and developmental abnormalities. Here, we provide an overview of the current understanding of the regulation of the p53 family by covalent modification by ubiquitin, SUMO-1, and NEDD8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.